{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:17:34Z","timestamp":1787840254654,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Bone is an endocrine organ that despite being inert in appearance constantly undergoes remodeling, in which wear and tear of bone cells occur. With more than two decades of clinical experience, the molecular mechanisms of anti-fracture drugs are not completely understood because they inhibit osteoclastic activity and differentiate the osteoblast cells. Recent studies suggest fundamentally different mechanisms of action for key anti-fracture drugs, bisphosphonates, and recombinant human parathyroid hormone (rhPTH) at the tissue level; however, their molecular basis of action has not been explored completely. Here, we showed the effect of varying concentrations of zoledronic acid (ZOL) and rhPTH on human osteogenic sarcoma cells (U2OS cells).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>Cellular viability, mineralization, and osteogenic gene expressions were assessed to elucidate the effects of these two prototypic drugs with diametrically different mechanisms of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Cellular viability was not affected either by ZOL or rhPTH alone or in tandem treatments. Osteoblastic activity increased significantly with rhPTH followed by ZOL. Further, alkaline phosphatase activity increased significantly with tandem treatment of rhPTH followed by ZOL both at the mRNA and protein levels. Moreover, osteoblastic genes (COL1A1 and osteocalcin) were significantly modulated by sequential treatment with rhPTH followed by ZOL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>We conclude that rhPTH (5 \u03bcg) treatment followed by ZOL (1 \u03bcM) showed the best anabolic or bone-forming effect. Our results warrant further research in assessing similar combinations of anti-fracture drugs, which augment osteogenesis to maximize their anabolic effects in preventing osteoporosis in susceptible individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_582_23","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:00:06Z","timestamp":1749783606000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study"],"prefix":"10.4103","volume":"57","author":[{"given":"Vandana","family":"Dhiman","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Kanta","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanjit","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bhansali","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devinder Kumar","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Panjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Pratap","family":"Barnwal","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Panjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpal","family":"Singh","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences Panjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhaker Dhanwada","family":"Rao","sequence":"additional","affiliation":[{"name":"Bone and Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"Suppl 3","key":"R1-20250613","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.2215\/CJN.04151206","article-title":"Normal bone anatomy and physiology","volume":"3","author":"Clarke","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.1670305","article-title":"Estrogen modulates osteoblast proliferation and function regulated by parathyroid hormone in osteoblastic SaOS-2 cells:Role of insulin-like growth factor (IGF)-I and IGF-binding protein-5","volume":"167","author":"Nasu","year":"2000","journal-title":"J Endocrinol"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMct1004903","article-title":"Bisphosphonates for osteoporosis","volume":"363","author":"Favus","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.c.31532","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"172","author":"Marom","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMcp1204713","article-title":"Clinical practice. Paget's disease of bone","volume":"368","author":"Ralston","year":"2013","journal-title":"N Engl J Med"},{"key":"R8-20250613","first-page":"1848","article-title":"Fibrous dysplasia. Pathophysiology, evaluation, and treatment","volume":"87","author":"DiCaprio","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease:Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX):A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3892\/mmr.2015.4627","article-title":"Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro","volume":"13","author":"Huang","year":"2016","journal-title":"Mol Med Rep"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1302\/2046-3758.61.BJR-2016-0085.R1","article-title":"Parathyroid hormone 1-34 and skeletal anabolic action:The use of parathyroid hormone in bone formation","volume":"6","author":"Osagie-Clouard","year":"2017","journal-title":"Bone Joint Res"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1359\/jbmr.070328","article-title":"Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells","volume":"22","author":"Datta","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1210\/endo-118-6-2445","article-title":"Parathyroid hormone stimulates the proliferation of cells derived from human bone","volume":"118","author":"MacDonald","year":"1986","journal-title":"Endocrinology"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bone.2007.11.017","article-title":"Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation","volume":"42","author":"Pettway","year":"2008","journal-title":"Bone"},{"key":"R20-20250613","first-page":"1325","article-title":"Interaction between osteoblast and osteoclast:Impact in bone disease","volume":"19","author":"Phan","year":"2004","journal-title":"Histol Histopathol"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/jc.2015-3698","article-title":"Effect of teriparatide on bone formation in the human femoral neck","volume":"101","author":"Cosman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/jbmr.2822","article-title":"Effects of daily or cyclic teriparatide on bone formation in the iliac crest in women on no prior therapy and in women on alendronate","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/jbmr.2804","article-title":"Alongitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw \u2013Do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures:Analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts:A systematic review from the research on Adverse Drug Events And Reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"J Bone Joint Surg Am"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3892\/or.2016.4986","article-title":"Parathyroid hormone\/parathyroid hormone-related peptide regulate osteosarcoma cell functions:Focus on the extracellular matrix (Review)","volume":"36","author":"Nikitovic","year":"2016","journal-title":"Oncol Rep"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1345\/aph.1D353","article-title":"Teriparatide for severe osteoporosis","volume":"38","author":"Cappuzzo","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1359\/JBMR.050821","article-title":"Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells","volume":"20","author":"van der Horst","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1025336114352","article-title":"Biglycan knockout mice:New models for musculoskeletal diseases","volume":"19","author":"Young","year":"2002","journal-title":"Glycoconj J"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000351194","article-title":"Zoledronic acid inhibits human osteoblast activities","volume":"59","author":"Basso","year":"2013","journal-title":"Gerontology"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_582_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:18:35Z","timestamp":1787836715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_582_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_582_23","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2023-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}